top of page

WELCOME TO iNANOD

NANO-TECHNOLOGY BASED CANCER DRUG DEVELOPMENT 

WHAT WE DO

iNANOD (2).png

Current developments in nanomedicine research has inspired iNANOD co-founders to start an entrepreneurial journey utilizing nanotechnology to improve cancer treatment.  iNANOD`s research is based on a nanotechnology-based platform, improving the efficacy and reducing side-effects of chemotherapeutic medications by optimizing drug delivery platform. This approach will ensure an optimal targeting and concentration of delivered drug to the diseased tissue. Our mission is to commercialize the research to benefit patients and society.

ABOUT 

iNANOD AS is a privately owned start-up company growing through the pull mechanism of innovation from the Oslo Cancer Cluster Incubator. iNANOD utilizes nano-biotechnology to establish a platform to improve drug delivery, especially within oncology. It has the ambition to deliver the active pharma ingredient in a targeted and accelerated way while generating immunotherapy. Therefore envisioning to kill cancer cells target-specifically by combined double actions of chemo and immunotherapy in solid malignant tumours.

Ready to take the next step? You can become a contributor to our research program, and investment that will support the strategy to improve cancer therapy by utilizing the potential of nanotechnology in medicine. In case you are an investor or a philanthropist looking to support iNANOD, please contact us.

ABOUT
WHAT WE DO

THE PEOPLE

BOARD MEMBERS

Portrait_004_Åge_Master.jpg

Åge Nærdal

Chairman

Linkedin icon.png

Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.

stener-kvinsland profil bilde_edited_edited.jpg

Stener Kvinnsland

Board member

Linkedin icon.png

MD with a PhD in oncology. Various roles in the pharmaceutical an biotech industry, former COB at Oslo University Hospital, former MD of Helse Bergen and former Director at Haukeland University Hospital. Specialist and professor in cancer medicine.

Per.jpg

Per Foss

Board member

Linkedin icon.png

Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.

Nalinava3.jpg

Nalinava Sengupta

Board Member & CEO

Linkedin icon.png

After 15 years of academic research in chemistry, turned entrepreneur for a mission.

WhatsApp Image 2022-12-12 at 15_edited.jpg

Thomas Due

Board member

Linkedin icon.png

He has over 20 years of Innovation and Venture Capital Fundraising experience in Norway. He has spent most of his adult life working where finance meets entrepreneurs. 

SUPPORTERS

362ee937-ec3f-477c-afa9-568899afa683-w_9
IN_Logo.png
OIH Logo.jpg

MEMBER OF

Logo-OCC.png
Logo_OCC_I_E_lang_cmyk.png
LifeScience_4.png
bottom of page